Adverse Event Clinical Trial
— EVIDENS-PrimOfficial title:
Patient Safety Incidents in Coordinated Primary Care Teams: a Multi-method Study
In France, improving the practice of health professionals working in coordinated primary care teams (health centres called Maisons de Santé Pluriprofessionnelles - MSPs) could be facilitated by a learning system consisting of (i) a risk management support programme and (ii) the provision of a comprehensive online system combining training, reporting and support for the analysis and management of patient safety incidents (PSIs). EVIDENS-Prim is a multi-method, multi-centre, prospective study. It aims to describe the PSIs that occur in MSPs, using an international classification system, and to describe the ways in which professionals have adopted a global approach to PSIs management, from PSI reporting to feedback.
Status | Not yet recruiting |
Enrollment | 15 |
Est. completion date | August 1, 2026 |
Est. primary completion date | July 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Characteristics of the MSPs included in the study: - Located in the Pays de la Loire region; - Having a contract with a health insurance (specifications and financing defined nationally) for at least 1 year; - Agreeing to take part in the project; - Having a quality representative or committing to appoint one when they join the project. Characteristics of professionals working in MSPs included: - All independent health professionals involved in the MSP: general practitioners and, depending on the MSP, nurses, pharmacists, podiatrists, physiotherapists, midwives, speech therapists, dentists, occupational therapists, psychomotor therapists, etc,) - All professionals involved in MSP outside the health sector: (coordinators, medical assistants, independent psychologists, etc.), - agree to take part in the project. Exclusion Criteria: Other group exercise modalities or other forms of coordinated exercise (other than MSP) do not have a quality representative on their team and will not be considered for inclusion. Characteristics of MSPs not included in the research: - Where the members of the research team work. Characteristics of professionals working in MSPs included: - Not included. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital | Université de Nantes |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Distribution of PSIs occurring in MSPs according to the 4 coding frameworks of the PISA classification: 1-by type | Repartition, according to the PISA classification, of PSIs reported by MSP professionals in the 18 months following the initial training provided, by type: the number of PSIs for each type out of the total number of PSIs reported. | PSIs reported by MSP professionals in the 18 months following the initial training provided | |
Primary | Distribution of PSIs occurring in MSPs according to the 4 coding frameworks of the PISA classification: 2- by contributing factors | Repartition, according to the PISA classification, of PSIs reported by MSP professionals in the 18 months following the initial training provided, by contributing factors : number of PSIs for each contributing factor (e.g. factors related to the patient, staff, equipment, organisation, etc.) out of the total number of PSIs reported. | 18 months | |
Primary | Distribution of PSIs occurring in MSPs according to the 4 coding frameworks of the PISA classification: 3-by results | Repartition, according to the PISA classification, of PSIs reported by MSP professionals in the 18 months following the initial training provided, by results: number of PSIs for each result (no harm, clinical harm, team harm) out of the total number of PSIs reported. | 18 months | |
Primary | Distribution of PSIs occurring in MSPs according to the 4 coding frameworks of the PISA classification: 4-by severity | Repartition, according to the PISA classification, of PSIs reported by MSP professionals in the 18 months following the initial training provided, by severity: number of PSIs of each severity (e.g. no harm, mild, moderate or severe harm, death) out of the total number of PSIs reported. | 18 months | |
Secondary | Description of MSP professionals' acceptance of learning system | Analysis of the main themes and sub-themes of the acceptability of the learning system from the semi-directed interviews and focus groups conducted with MSP professionals. | 3 months | |
Secondary | Description of the behaviour of users of the online system in the 18 months following the provision of initial training | Export from the web platform of
the number of professionals who have validated the opening of their account on the web platform, the number of professionals who have declared at least one PSI, the number of modifications made to the PSIs declaration, the number of declarations in anonymous mode, the number of updates of action sheets corresponding to improvement actions. |
18 months | |
Secondary | Description of the MSP's behaviour in implementing the risk management support programme during the 18 months following the provision of the initial training. | Description: Export from the web platform of
the number of PSI declarations the number of systemic analyses of PSIs carried out, the number of types of contributing factors identified by the analysis (variable categories defined according to the analysis methods), the number of analyses identifying security barriers (by type: present and effective / present and ineffective / absent), the number of improvement actions planned / completed / abandoned. |
18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Completed |
NCT05232656 -
PREventing Adverse Events Post-Discharge Through Proactive Identification, Multidisciplinary Communication, and Technology
|
N/A | |
Completed |
NCT03482232 -
Consequences of Doing What Should Not be Done in Primary Care
|
||
Completed |
NCT05693051 -
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
|
||
Completed |
NCT04055363 -
Human Milk Oligosaccharides (HMOs) Post-market Study on Infants
|
N/A | |
Completed |
NCT05133817 -
Prophylactic Norepinephrine Infusion Combined With Colloid Coloading for Postspinal Anesthesia Hypotension
|
N/A | |
Completed |
NCT02996201 -
Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT05462938 -
Conscious Sedation for Transcatheter Aortic Valve Implantation
|
N/A | |
Completed |
NCT04562922 -
LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy
|
Phase 2 | |
Recruiting |
NCT03740464 -
Long-acting G-CSF for Febrile Neutropenia
|
Phase 3 | |
Completed |
NCT03332433 -
High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol
|
N/A | |
Not yet recruiting |
NCT04615156 -
18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
|
Phase 3 | |
Recruiting |
NCT03381534 -
Safety and Efficacy of Distal Embolic Protection Device in Vertebral Artery Origin Stenting
|
N/A | |
Completed |
NCT04570488 -
Predicting Favorable Outcomes in Hospitalized Covid-19 Patients
|
||
Recruiting |
NCT05369962 -
Adverse Event Prediction in Geriatric Patients in the ED With Ultrasound
|
||
Completed |
NCT05321160 -
Comparison of the Sedation Effect of Esketamine and Sevoflurane for Pediatric Ophthalmological Procedure
|
N/A | |
Withdrawn |
NCT03673566 -
Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO
|
N/A | |
Completed |
NCT03745677 -
Redesigning Systems to Improve Quality for Hospitalized Patients
|
N/A | |
Completed |
NCT04763876 -
Intramuscular Ketorolac at Two Single-Dose Regimens
|
Phase 4 | |
Withdrawn |
NCT03673579 -
Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB
|
N/A |